|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical evaluation of bcl-2, ER-alpha, caspase -3, -8, -9, PCNA and Ki-67 expressions in canine mammary carcinomas.
|
29565181 |
2018 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
NRAGE promotes cell proliferation by stabilizing PCNA in a ubiquitin-proteasome pathway in esophageal carcinomas.
|
24710624 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
15-PGDH expression was significantly decreased in gastric carcinomas compared to corresponding non-neoplastic tissues and inversely correlated with the expression of proliferating cell nuclear antigen in gastric carcinomas.
|
19108014 |
2008 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis showed that Ki-67 and PCNA labeling indices were higher in the recurrent and metastasized carcinomas than in the primary cancer, suggesting that neoplastic cells become more malignant in the recurrent and metastasized foci.
|
16355395 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
P53 and PCNA protein accumulation in 25 patients with concurrent cancers from the esophagus and gastric cardia (CC, concurrent carcinomas of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma) were detected by immunohistochemical method (ABC).
|
12508343 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The data suggest that immunohistochemical investigation of PCNA and Ki67 and flow cytometric analysis of S-phase fractions may be useful predictive markers of biological aggressiveness in laryngeal carcinomas.
|
12520353 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Of the analyzed proliferative factors PCNA, cyclin A, cyclin D, cdk2, cdk4 and cell cycle phases only cyclin D, cdk4 and the cell cycle phases were up-regulated in growing carcinomas.
|
11788907 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The labeling index of proliferating cell nuclear antigen for the carcinomas in the LM group was higher than that in the no-LM group (47.1 +/- 24.5 vs. 26.2 +/- 24.5%, p < 0.0001).
|
12381909 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of FOS, JUN, ERBB1, and cyclin A or PCNA were decreased in carcinomas of patients with long-term survival.
|
12060626 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis of p53 and PCNA stainings in biopsy specimens appears to be a well-characterized indicator of sensitivity of chemotherapy in gastric carcinomas.
|
10948324 |
2001 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The PCNA labelling index in the BGP foci was significantly higher than that in the BGP negative mucosa (P< 0.001). p53 mutations were observed in 8 carcinomas, but no K-ras mutation was detected.
|
11384100 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, IL-1ra-positive adenomas contained more proliferating cell nuclear antigen-positive cells than IL-1ra-negative adenomas, indicating a link with high proliferation activity, although this was no longer evident in carcinomas.
|
10496524 |
1999 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using immunohistochemistry, expression of p53, transforming growth factor-alpha (TGF-alpha), epidermal growth factor receptor (EGFR), c-erbB-2/neu and proliferating cell nuclear antigen (PCNA) was examined in 26 fresh frozen tissue specimens of oropharyngeal squamous cell carcinomas (SCCs). p53 gene mutations were examined by polymerase chain reaction (PCR)/DNA sequencing methods in 22 carcinomas.
|
10621852 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin E and c-myc were positively correlated to cell proliferation in pre-cancerous lesions, but not related to overall survival in invasive carcinomas.
|
9891436 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin E staining was nuclear in distribution, and the frequency of positive staining, ie., moderate or strong intensity, was significantly higher (P < .001 for cyclin E staining vs. diagnosis) in all of the lesional epithelia (92.3, 51.6, and 50% of low-grade and high-grade SILs and carcinomas, respectively) compared with nonlesional epithelium (5.9%).
|
9872657 |
1998 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
No association was found between p21 or PCNA and apoptotic labeling indices in adenomas or carcinomas.
|
9607584 |
1998 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no correlation between PDGF expression and PCNA index in lung carcinomas.
|
9389786 |
1997 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The presence of oncogenic HPV DNAs (HPV-16/18) in cervical carcinomas and their normal and metastatic pelvic lymph nodes and the expression patterns of proliferating cell nuclear antigen (PCNA) in cervical carcinomas were retrospectively studied to elucidate the possible roles of them in malignant transformation and progression of the disease.
|
8774650 |
1996 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Because both follicular adenomas and carcinomas may be DNA aneuploid and their SPF and PCNA staining distributions overlap, the distinction between follicular adenoma and carcinoma should still be based on histological criteria.
|
7884588 |
1994 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Statistical significance was found between Type III (aneuploid carcinomas) and increased proliferating cell nuclear antigen expression (proliferating cell nuclear antigen score > or = 60 percent).
|
7956574 |
1994 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thirteen fibroadenomas and 39 carcinomas were examined for expression of Ki67 and PCNA.
|
7903289 |
1993 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry showed altered localization of p62c-myc, i.e., both cytoplasmic and nuclear immunostaining in advanced carcinomas. c-myc immunoreactivity exhibited wider distribution compared with that of PCNA, a cell cycle related antigen, which may indicate induction of cell proliferation by p62c-myc.
|
1444241 |
1992 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Proliferative activity was measured in 165 paraffin-embedded prostatic carcinomas using DNA flow cytometric analysis of the S-phase (SPF) and G2/M-phase fractions and CAS 200 image analysis of the proliferating cell nuclear antigen (PCNA) expression defined immunohistochemically by PC10 and 19A2 monoclonal antibodies.
|
1360498 |
1992 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Heterogeneity of expression of the proliferating cell nuclear antigen (PCNA) was assessed immunohistochemically in 156 tissue samples from 33 surgically resected pulmonary carcinomas using the monoclonal antibody 19A2.
|
1351473 |
1992 |